Cargando…

Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer

BACKGROUND: Enzalutamide, as a second-generation endocrine therapy drug for prostate cancer (PCa), is prominent representative among the synthetic androgen receptor antagonists. Currently, there is lack of enzalutamide-induced signature (ENZ-sig) for predicting progression and relapse-free survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Yuanfa, Deng, Yulin, Tang, Zhenfeng, Cai, Shanghua, Li, Jinchuang, Liu, Ren, Wan, Jiaming, He, Huichan, Zeng, Guohua, Ye, Jianheng, Han, Zhaodong, Zhong, Weide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060954/ https://www.ncbi.nlm.nih.gov/pubmed/37008945 http://dx.doi.org/10.3389/fendo.2023.1148898

Ejemplares similares

Identification and experimental validation of a tumor-infiltrating lymphocytes–related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma
por: Deng, Yulin, et al.
Publicado: (2022)

Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer
por: Ye, Jianheng, et al.
Publicado: (2023)

The prognostic roles of CYP19A1 expression in bladder cancer patients of different genders
por: Cai, Shanghua, et al.
Publicado: (2021)

Integrated analysis reveals prognostic value and progression-related role of AMIGO2 in prostate cancer
por: Han, Zhaodong, et al.
Publicado: (2022)

Differential Expression of E2F Transcription Factors and Their Functional and Prognostic Roles in Human Prostate Cancer
por: Han, Zhaodong, et al.
Publicado: (2022)

A reactive oxygen species–related signature to predict prognosis and aid immunotherapy in clear cell renal cell carcinoma
por: Liu, Hongxiang, et al.
Publicado: (2023)

TFEB Promotes Prostate Cancer Progression via Regulating ABCA2-Dependent Lysosomal Biogenesis
por: Zhu, Xuejin, et al.
Publicado: (2021)

Corrigendum: TFEB Promotes Prostate Cancer Progression via Regulating ABCA2-Dependent Lysosomal Biogenesis
por: Zhu, Xuejin, et al.
Publicado: (2021)

Acetyl-CoA carboxylase 1 depletion suppresses de novo fatty acid synthesis and mitochondrial β-oxidation in castration-resistant prostate cancer cells
por: Liu, Shaoyou, et al.
Publicado: (2022)

Prediction of Biochemical Recurrence-Free Survival of Prostate Cancer Patients Leveraging Multiple Gene Expression Profiles in Tumor Microenvironment
por: Zhou, Rui, et al.
Publicado: (2021)

Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer
por: Zou, Zhihao, et al.
Publicado: (2021)

Aberrant Expression of Citrate Synthase is Linked to Disease Progression and Clinical Outcome in Prostate Cancer
por: Cai, Zhiduan, et al.
Publicado: (2020)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
por: You, Xiangyun, et al.
Publicado: (2023)

Down-regulation of ACACA suppresses the malignant progression of Prostate Cancer through inhibiting mitochondrial potential
por: Zhang, Hui, et al.
Publicado: (2021)

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
por: Li, Qiuhui, et al.
Publicado: (2018)

Identification of a novel microRNA-mRNA regulatory biomodule in human prostate cancer
por: Zhang, Yanqiong, et al.
Publicado: (2018)

miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression
por: Cai, Chao, et al.
Publicado: (2018)

[Corrigendum] miR‑195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression
por: Cai, Chao, et al.
Publicado: (2023)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Identification and validation of a signature involving voltage-gated chloride ion channel genes for prediction of prostate cancer recurrence
por: Luo, Yong, et al.
Publicado: (2022)

Mitochondrion-associated protein peroxiredoxin 3 promotes benign prostatic hyperplasia through autophagy suppression and pyroptosis activation
por: Jiang, Min-Yao, et al.
Publicado: (2017)

A HIF1α-GPD1 feedforward loop inhibits the progression of renal clear cell carcinoma via mitochondrial function and lipid metabolism
por: Liu, Ren, et al.
Publicado: (2021)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)

Molecular determinants for enzalutamide-induced transcription in prostate cancer
por: Yuan, Fuwen, et al.
Publicado: (2019)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
por: Lopes, Nair, et al.
Publicado: (2021)

Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
por: Detert Oude Weme, S. E. H., et al.
Publicado: (2023)

Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
por: Smith, Rebecca, et al.
Publicado: (2020)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Enzalutamide: A New Agent for the Prostate Cancer Treatment Armamentarium
por: McCutcheon, Stephanie B.
Publicado: (2013)

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
por: Linder, Simon, et al.
Publicado: (2018)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

A comprehensive characterization of the transcriptome in enzalutamide resistance prostate cancer
por: Wang, Lili, et al.
Publicado: (2021)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
por: Graff, Julie N, et al.
Publicado: (2020)

hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro
por: Lim, Marvin C. J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3ddkql156s7ucv7gn55eg9bdja